Clinical-stage biotechnology company developing gene-editing technologies and therapeutic programs.
Independent editorial and sponsored coverage are visibly separated. Sponsored company reports carry a clear commercial-relationship disclosure and remain subject to the same sourcing, byline, date and correction standards as other newsroom reports.
The company is concentrating internal development on two lipid-disorder programs while exiting direct development of two cell-therapy assets.
Read full report →Send verifiable public material, a factual correction or a news tip to the editorial desk. Submissions are reviewed independently and do not guarantee publication.
